Annex 1 FAQs: How Did West Respond To The EU GMP Annex 1 Revision?

For packaging suppliers working in sterile drug product environments, the EU GMP Annex 1 revision's expanded focus on contamination control strategy means your component partners need to demonstrate the same rigor your own facility does.

Haley Johnson, Product Manager at West Pharmaceutical Services, explains how West approached the Annex 1 revision not as a compliance burden, but as a natural extension of practices already in place. Because contamination control wasn't a new concept for West, the revision became an opportunity to validate and communicate existing standards rather than build them from scratch.

If you're evaluating component partners for sterile applications or pressure-testing your own contamination control strategy against Annex 1 requirements, watch now to understand what a compliance-ready supplier looks like in practice.